Wells Fargo raises Church & Dwight stock price target on EPS outlook

Wells Fargo raised its Church & Dwight price target to $115 from $105 and maintained an Overweight rating, lifting its 2026 EPS estimate by $0.02 to $3.77 while keeping 2027 at $4.04. The firm forecasts EPS growth of 7% in both years and organic sales growth of 4.9% in 2026 and 3.8% in 2027, with potential estimate upside as the company pursues its 8% growth goal. Separately, Church & Dwight's reported Q3 2026 adjusted EPS of $0.92 and revenue of $1.6 billion exceeded forecasts of $0.90 and $1.58 billion, and the company raised its outlook.

Analysis

The key question is whether volume-led growth can persist without sacrificing price/mix or margins—not whether a small EPS estimate increase justifies a higher target. The bullish case is that repeat-purchase brands and international growth support estimate upgrades; the counterweight is that the valuation already sits near the upper end of CHD’s historical range, leaving limited room for execution misses. In consumer staples, sustained volume gains would be more informative than sales growth driven by pricing: they could indicate share gains against Procter & Gamble, Clorox and private-label alternatives, while also improving the durability investors assign to CHD’s premium multiple.

Near term, the earnings beat and raised outlook may already be reflected in sentiment; the next 1–3 months’ catalyst is evidence that organic volume and margins hold together, not another analyst target increase. Over 6–18 months, the test is whether international expansion and portfolio additions contribute growth without diluting returns or increasing integration risk. A contrarian risk is that “Evergreen” ambition encourages investors to capitalize aspirational growth before it is demonstrated. Watch reported organic volume, gross-margin direction, guidance revisions and the stock’s forward multiple versus peers. Thesis weakens if volume decelerates materially, margins contract, or management lowers its outlook; higher rates could also compress a premium staples multiple even if results remain sound.

Key Decisions for Investors

• Do not chase solely on the target increase: it relies on a premium earnings multiple, while the incremental estimate change described is modest. Check CHD’s current price and forward multiple before assessing remaining upside; those data are not supplied here.
• For a 1–3 month catalyst trade, consider a modest long CHD versus a broad consumer-staples ETF only if subsequent disclosures confirm volume growth and stable margins. Keep exposure limited; exit or reassess on a guidance reduction, sustained volume deceleration, or clear margin deterioration.
• Track CHD’s organic volume, price/mix and margin disclosures against P&G, Clorox and private-label competition. Volume slowing while price-led sales persist would challenge the share-gain thesis and raise the risk of multiple compression.
• Treat further estimate increases as confirmation, not a standalone catalyst. If the shares re-rate higher without corresponding upward revisions to earnings or guidance, favor taking profits or staying neutral rather than paying more for unchanged fundamentals.